BMS-663068 Tris is primarily used in the research and development of antiviral therapies, particularly for the treatment of HIV infections. It functions as a prodrug of BMS-626529, which is an attachment inhibitor targeting the gp120 protein on the surface of the HIV virus. By blocking the interaction between gp120 and the CD4 receptor on host cells, it prevents viral entry and replication. This compound is of significant interest in clinical studies aimed at developing next-generation antiretroviral drugs, especially for patients who have developed resistance to other classes of HIV medications. Its application is focused on improving treatment efficacy, reducing side effects, and offering alternative therapeutic options for managing HIV/AIDS.